The most frequently reported adverse events were gastrointestinal, including reduced appetite (61%) and nausea (56%)
Clinical trials have focused on people living with obesity, early research shows it could, if licensed, be used for conditions like type 2 diabetes and fatty liver disease
Maps failed to load Sorry, unable to load the Maps API
This level of low blood sugar is a medical emergency and must be treated immediately by a healthcare professional
This dual action enhances insulin secretion, reduces hunger even further, and may result in greater weight loss compared to Semaglutide
Retatrutide weight loss from Phase 2 and TRIUMPH-4 Retatrutide entered the clinical picture with a Phase 2 trial published in the New England Journal of Medicine